Keryx Biopharmaceuticals


FBR Remains Sidelined on Keryx Biopharmaceuticals (KERX) Following Analysis of Kidney Week Abstracts

On October 14th, the American Society of Nephrology (ASN) released the “Kidney Week Abstracts,” including five abstracts from Keryx Biopharmaceuticals’ (NASDAQ:KERX) Aurxyia (ferric …

Keryx Biopharmaceuticals’ (KERX) Auryxia Sales Expected To Go Nearly Zero: Cowen

Keryx Biopharmaceuticals (NASDAQ:KERX) just withdrew guidance for 2016 after an interrupted drug supply for its only pipeline drug, Auryxia, a drug created to …

Brean Capital Analyst Downgrades Keryx Biopharmaceuticals (KERX) Following Detrimental Auryxia Supply Disruption

Keryx Biopharmaceuticals (NASDAQ:KERX) shares are tumbling nearly 12% in early trading, following an impending supply interruption for key pipeline drug, Auryxia, a drug created …

Stock Update (NASDAQ:KERX): Keryx Biopharmaceuticals Announces Interruption in Supply of Auryxia® (ferric citrate) and Second Quarter 2016 Financial Results

Keryx Biopharmaceuticals (NASDAQ:KERX) announced that an interruption in the supply of Auryxia® (ferric citrate) tablets is imminent due to a production-related issue converting active …

FBR Analyst Comments on Keryx Biopharmaceuticals (KERX) Ahead of 2Q:16 Earnings Results

After an encouraging update from Keryx Biopharmaceuticals (NASDAQ:KERX) management about approved drug Auryxia, a phosphate binder designed to treat iron deficiency anemia (IDA) …

Maxim Lifts Price Target On Keryx Biopharmaceuticals (KERX); Here’s Why

In a research report published Friday, Maxim analyst Jason Kolbert reiterated a Buy rating on shares of Keryx Biopharmaceuticals (NASDAQ:KERX), while raising the price …

Stock Update (NASDAQ:KERX): Douglas Jermasek to Join Keryx Biopharmaceuticals as Vice President, Marketing and Strategy

Keryx Biopharmaceuticals (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced that Douglas Jermasek will join the …

Company Update (NASDAQ:KERX): Keryx Biopharmaceuticals Appoints Two New Board Members

Keryx Biopharmaceuticals (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, announced that Michael Heffernan and Jodie Morrison joined …

Thursday’s Morning Insights: Repros Therapeutics Inc (RPRX), Keryx Biopharmaceuticals (KERX), and Conn’s Inc (CONN)

Repros Therapeutics Inc (NASDAQ:RPRX) is soaring nearly 19% this morning to $2.01 following yesterday’s positive news that provided an update on the company’s …

Sell-Side Analysts Weigh In on Two Small Cap Biotechs: Advaxis, Inc. (ADXS) and Keryx Biopharmaceuticals (KERX)

Healthcare analysts at sell-side firms FBR and Brean Capital were out today with some commentary on small-cap biotech companies Advaxis, Inc. (NASDAQ:ADXS) and Keryx Biopharmaceuticals (NASDAQ:KERX).